Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.

Participants receiving liraglutide had a small mean improvement of 0.87 points in the physical component of the SF-36 compared with placebo (very low-quality evidence).

In plain wordsPeople on liraglutide reported a small improvement in physical quality of life compared with placebo.

Measurements

SF-36 physical component difference

0.87 points

liraglutide vs placebo

Source sentences

In people at risk of type 2 diabetes, 2 of 1501 participants on liraglutide 3.0 mg and 2 of 747 on placebo died after 160 weeks (very low-quality evidence).

In plain wordsIn people at risk of type 2 diabetes, deaths were equally rare with liraglutide 3.0 mg and with placebo over 160 weeks.

Source sentences

In people at risk of type 2 diabetes, 26 of 1472 participants on liraglutide 3.0 mg developed type 2 diabetes versus 46 of 738 on placebo after 160 weeks (very low-quality evidence).

In plain wordsIn people at risk of type 2 diabetes, fewer developed diabetes on liraglutide 3.0 mg than on placebo over 160 weeks.

Source sentences

In people with intermediate hyperglycaemia, 66% of participants on liraglutide regressed to normoglycaemia compared with 36% on placebo; the abstract's count of 70/1472 does not match its 66%.

In plain wordsIn people with intermediate hyperglycaemia, the reported share who returned to normal blood sugar was higher with liraglutide than with placebo.

Source sentences

After the 12-week off-treatment extension, five additional participants were diagnosed with type 2 diabetes in the liraglutide group compared with one in the placebo group.

In plain wordsAfter treatment stopped for 12 weeks, five more people on liraglutide and one more on placebo were diagnosed with diabetes.

Source sentences

After 12 weeks off treatment, 740 of 1472 participants in the liraglutide group had normoglycaemia compared with 263 of 738 in the placebo group.

In plain wordsAfter 12 weeks off treatment, more people who had taken liraglutide had normal blood sugar than those who had taken placebo.

Source sentences

In people at risk of type 2 diabetes, serious adverse events occurred in 230 of 1524 participants on liraglutide 3.0 mg versus 96 of 755 on placebo (very low quality evidence); no statistical test is reported.

In plain wordsIn people at risk of type 2 diabetes, serious side effects were numerically more frequent with liraglutide 3.0 mg than with placebo.

Source sentences

Non-fatal myocardial infarction was reported in 1 of 1524 participants in the liraglutide arm and 0 of 55 in the placebo arm at 172 weeks (very low-quality evidence).

In plain wordsHeart attacks were very rare: one in the liraglutide group and none in the small placebo group at 172 weeks.

Source sentences

Congestive heart failure was reported in 1 of 1524 participants in the liraglutide arm and 1 of 755 in the placebo arm (very low-quality evidence).

In plain wordsHeart failure was very rare, with one case in the liraglutide group and one in the placebo group.

Source sentences